Literature DB >> 27438448

Establishment of Patient-Derived Keloid Xenograft Model.

Tae Hwan Park1, Dong Kyun Rah, Choong Hyun Chang, Sung Young Kim.   

Abstract

Recent advances on preclinical model based on patient-derived tumor xenografts have new insight into many clinical fields. According to our literature review, many authors believe that immunodeficient animals such as athymic rats and mice should be used to prevent tissue loss caused by acute rejection to establish patient-derived tumor xenografts models.However, recent advances showed that the microenvironment has gained attention as an important factor responsible for disease progression. Additionally, researchers attempt to come up with novel findings in chemotherapy drugs and immune modulator to control development of keloid. For these reasons, establishment of reliable animal model of keloids is very important.In this new model using an immunocompetent animal as a humanized-xenografts model, human keloid scar has been maintained for as long as 4 months. Results of migration assay have demonstrated that typical morphology of keloid fibroblast was preserved based on multiple time point observations despite its aging change. Quantitative real time polymerase chain reaction findings suggested that after implantation, there has been significant increase of vascular endothelial growth factor, CD34, and transforming growth factor beta 1 expression despite insignificant changes of hypoxia inducible factor 1 an matrix metallopeptidase 1, and matrix metallopeptidase 9 gene expression. These findings suggested that implantation of keloids within the immunocompetent animals yields is very useful experimental model in terms of fibrosis.In summary, the authors have successfully established and propagated patient-derived keloid model using the immunocompetent animals. This model could be used to test novel materials as well as combination therapies and is superior to the conventional cell line experiment models. In addition, the biology of the keloids can easily be assessed to identify predictive markers for responses to treatment regimens that are currently actively under research in various centers.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27438448     DOI: 10.1097/SCS.0000000000002901

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  4 in total

1.  Botulinum toxin A increases allograft tolerance in an experimental transplantation model: a preliminary study.

Authors:  Yun Joo Park; Jang Won Lee; Yosep Chong; Tae Hwan Park
Journal:  Biosci Rep       Date:  2018-03-21       Impact factor: 3.840

2.  Hsa_circ_0074298 promotes pancreatic cancer progression and resistance to gemcitabine by sponging miR-519 to target SMOC.

Authors:  Chen Hong; Wang Lishan; Xie Peng; Lei Zhengqing; Yang Yang; Hu Fangfang; Yu Zeqian; Cheng Zhangjun; Zhou Jiahua
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

3.  Radiation-induced FAP + fibroblasts are involved in keloid recurrence after radiotherapy.

Authors:  Yan Gao; Xue Hou; Yuyin Dai; Ting Yang; Kexin Chen
Journal:  Front Cell Dev Biol       Date:  2022-08-24

4.  Inhibition of growth of Asian keloid cells with human umbilical cord Wharton's jelly stem cell-conditioned medium.

Authors:  Subramanian Arjunan; Shu Uin Gan; Mahesh Choolani; Vaishnevi Raj; Jane Lim; Arijit Biswas; Ariff Bongso; Chui Yee Fong
Journal:  Stem Cell Res Ther       Date:  2020-02-21       Impact factor: 6.832

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.